आइबुप्रोफेन और फैमोटिडीन के इंटरैक्शन

It should not be used with other ibuprofen-containing products. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

• Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs). (एकालाब्रुटिनिब लेबल, दवाओं के इंटरैक्शन)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (एडोक्साबैन लेबल, बॉक्स्ड चेतावनी)

…the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (एनोक्सापैरिन लेबल, बॉक्स्ड चेतावनी)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (एपिक्साबैन लेबल, बॉक्स्ड चेतावनी)

Avoid SYMFI with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.3) ] . (एफाविरेंज़, लैमिवुडिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Moderate or Weak CYP1A2 Inhibitors Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. (टिज़ानिडिन लेबल, दवाओं के इंटरैक्शन)

VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (टेनोफोविर लेबल, चेतावनियां और सावधानियां)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Use of KEVEYIS with drugs that are sensitive to OAT1 inhibition (e.g., methotrexate, famotidine, oseltamivir) is not recommended [see Clinical Pharmacology (12.3) ]. (डाइक्लोरफेनामाइड लेबल, दवाओं के इंटरैक्शन)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Intervention Concomitant administration of ibuprofen and famotidine tablet is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (डैबिगैट्रान लेबल, बॉक्स्ड चेतावनी)

Ibuprofen and famotidine tablet should not be administered to patients with a history of hypersensitivity to other H 2 -receptor antagonists. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

It should not be used with other ibuprofen-containing products. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (प्रालाट्रेक्सेट लेबल, दवाओं के इंटरैक्शन)

Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (प्रासुग्रेल लेबल, बॉक्स्ड चेतावनी)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Ibuprofen and famotidine tablet should not be administered to patients with a history of hypersensitivity to other H 2 -receptor antagonists. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (फोंडापैरिनक्स लेबल, बॉक्स्ड चेतावनी)

Intervention Concomitant administration of ibuprofen and famotidine tablet is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Intervention: The concomitant use of ibuprofen and famotidine tablet with other NSAIDs or salicylates is not recommended. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: The concomitant use of ibuprofen and famotidine tablet with other NSAIDs or salicylates is not recommended. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Intervention Concomitant use of methylphenidate extended-release orally disintegrating tablets with a gastric pH modulator (i.e., a H2-blocker or a proton pump inhibitor) is not recommended. (मिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (मिसोप्रोस्टोल लेबल, बॉक्स्ड चेतावनी)

Unexpectedly severe and fatal gastrointestinal toxicity can occur with concomitant administration of XATMEP (primarily at high dosage) and nonsteroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions ( 7.1 )] . (मेथोट्रेक्सेट लेबल, चेतावनियां और सावधानियां)

Intervention: The concomitant use of ibuprofen and famotidine tablet with other NSAIDs or salicylates is not recommended. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Intervention: The concomitant use of ibuprofen and famotidine tablet with other NSAIDs or salicylates is not recommended. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (मोंटेलुकास्ट लेबल, चेतावनियां और सावधानियां)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (रिवारोक्साबैन लेबल, बॉक्स्ड चेतावनी)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Ibuprofen and famotidine tablet should not be administered to patients with a history of hypersensitivity to other H 2 -receptor antagonists. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Intervention: The concomitant use of ibuprofen and famotidine tablet with other NSAIDs or salicylates is not recommended. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (सिडोफोविर लेबल, दवाओं के इंटरैक्शन)

Ibuprofen and famotidine tablet should not be administered to patients with a history of hypersensitivity to other H 2 -receptor antagonists. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (आइबुप्रोफेन और फैमोटिडीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

It should not be used with other ibuprofen-containing products. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (अफाटिनिब लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Nonsteroidal Anti-Inflammatory Drugs Meloxicam Concomitant drug dose increase may be necessary. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (इबैंड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (उपाडासिटिनिब लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

An H2RA dose comparable to famotidine 20 mg once daily up to a dose comparable to famotidine 40 mg twice daily can be used with REYATAZ 300 mg with ritonavir 100 mg in treatment-naive patients. (एटाज़ानाविर लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (एडेफोविर लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (एनाग्रेलाइड लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (एमट्रिसिटाबिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (एर्लोटिनिब लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Use caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. (एलेंड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (ऑक्ट्रियोटाइड लेबल, दवाओं के इंटरैक्शन)

Non Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of CNS stimulation and convulsive seizures (see WARNINGS and PRECAUTIONS , General ). (ओफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Drugs that may decrease ketoconazole plasma concentrations Drugs that reduce the gastric acidity (e.g., acid neutralizing medicines such as aluminum hydroxide, or acid secretion suppressors such as H 2 -receptor antagonists and proton pump inhibitors) impair the absorption of ketoconazole from ketoconazole tablets. (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Tizanidine (CYP1A2 Substrate) Clinical Impact Famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (गैलेंटामिन लेबल, चेतावनियां और सावधानियां)

…angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. (ग्लिपिज़ाइड लेबल, दवाओं के इंटरैक्शन)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (ग्लिपिज़ाइड और मेटफॉर्मिन लेबल, सावधानियां)

Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (ग्लिबेनक्लामाइड लेबल, दवाओं के इंटरैक्शन)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Tizanidine (CYP1A2 Substrate) Clinical Impact Famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (जेफिटिनिब लेबल, दवाओं के इंटरैक्शन)

There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug. (ज़ेलेप्लॉन लेबल, दवाओं के इंटरैक्शन)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (ज़ोलेड्रोनिक एसिड लेबल, दवाओं के इंटरैक्शन)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

…physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (टोफासिटिनिब लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Digoxin Clinical Impact: The concomitant use of ibuprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Tizanidine (CYP1A2 Substrate) Clinical Impact Famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (डेस्मोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

…↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric… (डैपाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (डोनेपेज़िल लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (निंटेडानिब लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Table 2: Clinically Significant Drug Interactions with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone),… (नेटेग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (पियोग्लिटाज़ोन और ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (पोटैशियम क्लोराइड लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (पोटैशियम साइट्रेट लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

…Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone,… (फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (फेबुक्सोस्टैट लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

…Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone,… (फॉस्फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Similarly, the C max and AUC of the pharmacologically active isomer [S-(+)-ibuprofen] were increased by 15% and 82%, respectively, when fluconazole was coadministered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone. (फ्लुकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (बोसुटिनिब लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

When given concomitantly with mifepristone, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. [See Clinical Pharmacology ( 12.3 )] 7.5 Drugs Metabolized by CYP2B6 Mifepristone is an… (मिफेप्रिस्टोन लेबल, दवाओं के इंटरैक्शन)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Tizanidine (CYP1A2 Substrate) Clinical Impact Famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (मेमेंटिन और डोनेपेज़िल लेबल, चेतावनियां और सावधानियां)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (मॉक्सीफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Anaphylactic Shock and Hypersensitivity Reactions: Premedicate all patients with a combination of an H1-antihistamine, an H2 blocker, and a leukotriene inhibitor prior to each APHEXDA dose. (मोटिक्साफोर्टाइड लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

H 2 -Receptor Antagonists: cimetidine famotidine nizatidine ranitidine ↔ rilpivirine (famotidine taken 12 hours before rilpivirine or 4 hours after rilpivirine) The combination of EDURANT or EDURANT PED and H 2 -receptor antagonists should be used with caution as coadministration may cause significant decreases in rilpivirine plasma concentrations (increase in… (रिल्पिविरिन लेबल, दवाओं के इंटरैक्शन)

Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (रिवास्टिग्मिन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Lithium Clinical Impact: NSAIDs have produced elevations of plasma lithium levels and reductions in renal lithium clearance. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Concomitant Drug Class: Drug Name Effect on Concentration ↓ = decrease, ↑ = increase Clinical Comment tenofovir DF = tenofovir disoproxil fumarate Acid Reducing Agents: ↓ ledipasvir Ledipasvir solubility decreases as pH increases. (लेडिपासविर और सोफोसबुविर लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (लेवोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. (वोरिकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

• Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (वोर्टियोक्सेटिन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Cyclosporine Clinical Impact: Concomitant use of ibuprofen and cyclosporine may increase cyclosporine’s nephrotoxicity. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Tizanidine (CYP1A2 Substrate) Clinical Impact Famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (सेफोटैक्सिम लेबल, दवाओं के इंटरैक्शन)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Clinical Effect/Recommendation Acid Reducing Agents: ↓ velpatasvir Velpatasvir solubility decreases as pH increases. (सोफोसबुविर और वेल्पाटासविर लेबल, दवाओं के इंटरैक्शन)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

एसिड कम करने वाली दवाएं पेट का एसिड घटाती हैं और सप्लीमेंट और भोजन से अवशोषित होने वाले आयरन की मात्रा कम कर सकती हैं। (NIH Office of Dietary Supplements, Iron)

In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (इन्फ्लिक्सिमैब लेबल, दवाओं के इंटरैक्शन)

…fluconazole, voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, quinine, quinupristin, ticlopidine, troleandomycin, valproate, verapamil,… (कार्बामाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (ग्लिबेनक्लामाइड और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

…drug-drug interactions have not been observed or are not anticipated with concomitant use of darunavir and cobicistat with rilpivirine, dolutegravir, raltegravir, abacavir, emtricitabine, emtricitabine/tenofovir alafenamide, tenofovir DF, lamivudine, stavudine, zidovudine, or acid modifying medications (antacids, H 2 -receptor antagonists, proton pump inhibitors). (डारुनाविर और कोबिसिस्टैट लेबल, दवाओं के इंटरैक्शन)

For administration instructions of other drugs whose absorption is dependent on gastric pH, refer to their prescribing information (e.g., atazanavir, erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine). (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (पाइलोकार्पिन लेबल, दवाओं के इंटरैक्शन)

…angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (फिनास्टेराइड लेबल, दवाओं के इंटरैक्शन)

Therapeutic levels of aspirin, desipramine, diazepam, flurazepam, ibuprofen, propranolol, thioridazine, and tolbutamide had only a limited effect on the extent of binding of buspirone to plasma proteins (see CLINICAL PHARMACOLOGY ). (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

No change in choice reaction time or sedation index was detected after dosing with the H2 receptor antagonists. (मिडाज़ोलम लेबल, दवाओं के इंटरैक्शन)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

Other drugs: Carbamazepine Furosemide (>80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs Fenamates These drugs may cause protein binding site displacement. (लियोथायरोनिन लेबल, दवाओं के इंटरैक्शन)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (लेनालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-Inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. (लेवोथायरोक्सिन लेबल, दवाओं के इंटरैक्शन)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

एसिड कम करने वाला लंबे समय का इलाज भोजन से B12 के अवशोषण में बाधा डालता है और इसकी कमी का कारण बन सकता है। (NIH Office of Dietary Supplements, Vitamin B12)

Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H 2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. (सेफाक्लोर लेबल, दवाओं के इंटरैक्शन)

…Significant Interactions with Efavirenz No dosage adjustment is recommended when efavirenz is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lorazepam, nelfinavir, nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, zidovudine),… (एफाविरेंज़ लेबल, दवाओं के इंटरैक्शन)

…ampicillin, with or without sulbactam atenolol azithromycin caffeine, dietary ingestion cefaclor co-trimoxazole (trimethoprim and sulfamethoxazole) diltiazem dirithromycin enflurane famotidine felodipine finasteride hydrocortisone isoflurane isoniazid isradipine influenza vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole… (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Drugs Having No Clinically Important Interactions with ABILIFY MAINTENA Based on pharmacokinetic studies with oral aripiprazole, no dosage adjustment of ABILIFY MAINTENA is required when administered concomitantly with famotidine, valproate, lithium, lorazepam [see Clinical Pharmacology (12.3) ] . (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Effects of Concomitant Acid Blockers or Antibiotics A population pharmacokinetic analysis suggests that the pharmacokinetics of alvimopan were not affected by concomitant administration of acid blockers (proton pump inhibitors (PPIs), histamine-2 (H 2 ) receptor antagonists) or antibiotics. (एल्विमोपैन लेबल, दवाओं के इंटरैक्शन)

…safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.3 Cimetidine In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile… (डेसलोराटाडीन लेबल, दवाओं के इंटरैक्शन)

…nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride Sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline,… (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

No clinically relevant effects on the pharmacokinetics of Noxafil delayed-release tablets were observed during concomitant use with antacids, H 2 -receptor antagonists and proton pump inhibitors, and metoclopramide [see Clinical Pharmacology (12.3) ] . (पोसाकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (रोपिनिरोल लेबल, दवाओं के इंटरैक्शन)

…triazolam is concomitantly administered with SUNLENCA 7.4 Drugs without Clinically Significant Interactions with SUNLENCA Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with: darunavir/cobicistat, cobicistat, famotidine, pitavastatin, rosuvastatin, tenofovir alafenamide, and voriconazole. (लेनाकैपाविर लेबल, दवाओं के इंटरैक्शन)